Compare Gap Inc (GAP) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Johnson & Johnson — how do they compare? Gap Inc trades at $23.31 (market cap $8.21B), while Johnson & Johnson trades at $260.22 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 75.3× Gap Inc's market cap, and Gap Inc pays the higher dividend (3%). Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Johnson & Johnson for 129 Days on average.
| GAP | JNJ | |
|---|---|---|
Market Cap | $8.21B | $618.09B |
Volume | 5,192,917 | 6,050,983 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $278.43 |
52-Week Low | $18.35 | $186.00 |
Typical Hold Time | 37 Days | 129 Days |
Enterprise Value | $11.44B | $646.37B |
Dividend Yield | 3% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap Inc. (GAP) trades at $23.15, down 1.95% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $25.67. The company shows strong profitability with a net income margin of 8.14% and ROE of 33.78%, supported by recent earnings beats in Q1 and Q2 2026. Recent developments include a 'fashiontainment' partnership with boy band JYT and a new board appointment, signaling strategic brand revitalization efforts.
The outlook for Gap is cautiously optimistic, with valuation metrics like a P/E of 7.04 and P/S of 0.58 suggesting potential upside. Key risks include uneven brand performance, with Old Navy sales declining, and macroeconomic pressures on consumer spending. Earnings growth and successful brand initiatives are critical catalysts for further stock appreciation.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
